Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

blonca9
Dec 22, 2023
1 min read

Co-Founder & CEO Ashley Zehnder describes how Fauna studies animals that have disease resistance and how the company leverages understandings from this to tackle human disease. On Thursday, Fauna signed a deal with Eli Lilly worth up to $494 million to collaborate on obesity targets.

Recent Posts

See All

RBC Global Healthcare Conference: Korro Bio entered the clinic with its RNA editing platform in January and will have multiple cohorts of data in AATD later this year

RBC Global Healthcare Conference: With a phase 3 for its lead program scheduled to read in Q3 and mid-stage data for another program coming up this quarter, aTyr Pharma has pivotal months ahead

RBC Global Healthcare Conference: Ocular Therapeutix's Chairman & CEO Pravin Dugel provides an update on the progress of the pivotal studies for AXPAXLI in wet AMD

Fauna Bio signs collaboration with Lilly to leverage understandings from hibernation to discover novel obesity targets

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight